Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease

Experimental Cell Research

Volumn 317, Issue 11, 2011, Pages 1527-1533

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Frascerra, Silvia ^a   Corrado, Alda ^a   Pupilli, Cinzia ^b   Bernini, Giampaolo ^a   Benvenga, Salvatore ^c   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

CCL2; CXCL10; Graves' disease; PPAR ; Thyrocyte

Indexed keywords

CHEMOKINE; CIPROFIBRATE; FENOFIBRATE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMFIBROZIL; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; THIAMAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; THYROID CELL; THYROID DISEASE; THYROID FOLLICLE CELL; THYROIDECTOMY;

EID: 79956327190     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.04.007     Document Type: Article

References (32)

1. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., Ferrannini E., Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J. Clin. Endocrinol. Metab. 2004, 89:5496-5499.
2. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., Serio M., Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2006, 91:614-620.
3. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2009, 94:1803-1809.
4. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997, 272:3406-3410.
5. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
6. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7:48-52.
7. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 2002, 168:2795-2802.
8. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 2000, 164:6503-6508.
9. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 1999, 274:32048-32054.
10. Spencer N.F., Poynter M.E., Im S.Y., Daynes R.A. Constitutive activation of NF-kappa B in an animal model of aging. Int. Immunol. 1997, 9:1581-1588.
11. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 2000, 275:36703-36707.
12. Lee J.W., Bajwa P.J., Carson M.J., Jeske D.R., Cong Y., Elson C.O., Lytle C., Straus D.S. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 2007, 133:108-123.
13. Kasai K., Banba N., Hishinuma A., Matsumura M., Kakishita H., Matsumura M., Motohashi S., Sato N., Hattori Y. 15-Deoxy-delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes. Am. J. Physiol. Cell Physiol. 2000, 279:C1859-C1869.
14. Antonelli A., Ferrari S.M., Frascerra S., Pupilli C., Mancusi C., Metelli M.R., Orlando C., Ferrannini E., Fallahi P. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-{alpha} agonists secretion in Graves' and normal thyrocytes. J. Clin. Endocrinol. Metab. 2010, 95:E413-E420.
15. Marazuela M., Postigo A.A., Acevedo A., Diaz-Gonzalez F., Sanchez-Madrid F., De Landazuri M.O. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur. J. Immunol. 1994, 24:2483-2490.
16. Garcià-Lòpez M.A., Sancho D., Sànchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J. Clin. Endocrinol. Metab. 2001, 86:5008-5016.
17. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Piaggi S., Gelmini S., Lupi C., Minuto M., Berti P., Benvenga S., Basolo F., Orlando C., Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr. Relat. Cancer 2009, 16:1299-1311.
18. Antonelli A., Ferrari S.M., Fallahi P., Berti P., Materazzi G., Minuto M., Giannini R., Marchetti I., Barani L., Basolo F., Ferrannini E., Miccoli P. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol. (Oxf.) 2009, 70:946-953.
19. Antonelli A., Bocci G., La Motta C., Ferrari S.M., Fallahi P., Fioravanti A., Sartini S., Minuto M., Piaggi S., Corti A., Alì G., Berti P., Fontanini G., Danesi R., Da Settimo F., Miccoli P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2011, 96:E288-E296.
20. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., Ferrannini E., Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur. J. Endocrinol. 2005, 152:171-177.
21. Chen K., Wei Y., Alter A., Sharp G.C., Braley-Mullen H. Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis. J. Leukoc. Biol. 2005, 78:716-724.
22. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
23. Majumder S., Zhou L.Z., Chaturvedi P., Babcock G., Aras S., Ransohoff R.M. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J. Immunol. 1998, 161:4736-4744.
24. Leung T.H., Hoffmann A., Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. Cell 2004, 118:453-464.
25. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
26. Antonelli A., Ferrari S.M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S.S., Salvi M., Ferrannini E. Cytokines (interferon-gamma and tumor necrosis factor-alpha)-induced nuclear factor-kappaB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011, 60:277-283.
27. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., Schlezinger J., Sherr D., Saubermann L.J. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis. 2005, 11:244-252.
28. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., Ceni E., Varano G., Forti G., Rotondi M., Galli A., Serio M., Luconi M. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:718-724.
29. Lee J.H., Joe E.H., Jou I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. Neuroreport 2005, 16:829-833.
30. Rival Y., Benéteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoiseau J.F., Junquéro D., Colpaert F.C., Delhon A. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 2002, 435:143-151.
31. Dragomir E., Tircol M., Manduteanu I., Voinea M., Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul. Pharmacol. 2006, 44:440-449.
32. Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J. Biol. Chem. 2005, 280:2550-2561.